{"id":"azd5335","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AZD5335 targets FGFR1, a receptor tyrosine kinase frequently dysregulated in various cancers through gene amplification or activating mutations. By inhibiting FGFR1 phosphorylation and downstream signaling, the drug suppresses tumor cell proliferation and survival in FGFR1-dependent malignancies. This selective approach aims to provide efficacy while potentially reducing off-target toxicities associated with pan-FGFR inhibitors.","oneSentence":"AZD5335 is a selective inhibitor of fibroblast growth factor receptor 1 (FGFR1) that blocks aberrant FGFR signaling in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:09.436Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"FGFR1-amplified or FGFR1-driven solid tumors (in development)"}]},"trialDetails":[{"nctId":"NCT05797168","phase":"PHASE1, PHASE2","title":"Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-06-05","conditions":"Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer","enrollment":506},{"nctId":"NCT07402915","phase":"PHASE1","title":"Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-26","conditions":"Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal","enrollment":24},{"nctId":"NCT07218809","phase":"PHASE3","title":"AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-29","conditions":"Epithelial Ovarian Cancer","enrollment":1100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AZ14170132"],"phase":"phase_3","status":"active","brandName":"AZD5335","genericName":"AZD5335","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD5335 is a selective inhibitor of fibroblast growth factor receptor 1 (FGFR1) that blocks aberrant FGFR signaling in cancer cells. Used for FGFR1-amplified or FGFR1-driven solid tumors (in development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}